Achaogen is focused on developing innovative antibiotics for the treatment of serious infections caused by multi-drug resistant bacteria, particularly in the area of complicated urinary tract infections (cUTI)
Achaogen is focused on developing innovative antibiotics for the treatment of serious infections caused by multi-drug resistant bacteria, particularly in the area of complicated urinary tract infections (cUTI). Their lead product, ZEMDRI (plazomicin), is an aminoglycoside antibiotic indicated for adult patients with cUTI.